- • NeoGenomics Reports Revenue of $63.4 Million, Net Income of $0.6 Million and Adjusted EBITDA of $9.2 Million in the First Quarter of 2018
- • FDA Authorizes CTD to Proceed with Extension Protocol to US Phase I Trappsol(R) Cyclo(TM) Trial for Niemann-Pick Disease Type C
- • Robert A. Essner, former Chairman and Chief Executive of Wyeth, named Executive Chairman of Elucida Oncology, Inc.
- • Avalon GloboCare Forms Joint Laboratory with Top-Ranked Hospital in Shanghai for Regenerative Exosomics
- • CTD Holdings Closes $2.00 Million Private Placement
TRUSTED COMPANIES WE REPRESENT